For example, the Genentech group has shown that treatment of tumor-bearing mice with a highly selective anti-Mertk neutralizing antibody impairs macrophage efferocytosis, resulting in the release of danger signals such as ATP and cGAS that activate macrophages to help stimulate host immunity to cancer cells [207]. This evidence concerns the gene MERTK and neoplasm.